Bahar Yetkin-Arik

2.1k total citations · 1 hit paper
11 papers, 1.1k citations indexed

About

Bahar Yetkin-Arik is a scholar working on Molecular Biology, Cell Biology and Cancer Research. According to data from OpenAlex, Bahar Yetkin-Arik has authored 11 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Cell Biology and 3 papers in Cancer Research. Recurrent topics in Bahar Yetkin-Arik's work include Angiogenesis and VEGF in Cancer (5 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Congenital heart defects research (3 papers). Bahar Yetkin-Arik is often cited by papers focused on Angiogenesis and VEGF in Cancer (5 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Congenital heart defects research (3 papers). Bahar Yetkin-Arik collaborates with scholars based in Netherlands, Switzerland and Slovenia. Bahar Yetkin-Arik's co-authors include Pieter Wesseling, Helga E. de Vries, Tom Würdinger, Olaf van Tellingen, Mark C. de Gooijer, Reinier O. Schlingemann, Cornelis J.F. Van Noorden, Ingeborg Klaassen, Ilse M. C. Vogels and Riekelt H. Houtkooper and has published in prestigious journals such as PLoS ONE, Scientific Reports and Acta Neuropathologica.

In The Last Decade

Bahar Yetkin-Arik

11 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overcoming the blood–brain tumor barrier for effective glioblastoma treatment

2015 764 citations Olaf van Tellingen, Bahar Yetkin-Arik et al. Drug Resistance Updates profile →

Peers

Countries citing papers authored by Bahar Yetkin-Arik

Since Specialization

Citations

This map shows the geographic impact of Bahar Yetkin-Arik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bahar Yetkin-Arik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bahar Yetkin-Arik more than expected).

Fields of papers citing papers by Bahar Yetkin-Arik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bahar Yetkin-Arik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bahar Yetkin-Arik. The network helps show where Bahar Yetkin-Arik may publish in the future.

Co-authorship network of co-authors of Bahar Yetkin-Arik

This figure shows the co-authorship network connecting the top 25 collaborators of Bahar Yetkin-Arik. A scholar is included among the top collaborators of Bahar Yetkin-Arik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bahar Yetkin-Arik. Bahar Yetkin-Arik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Mesenchymal stromal/stem cells promote intestinal epithelium regeneration after chemotherapy-induced damage 2024 ·Stem Cell Research & Therapy ·Bahar Yetkin-Arik, Suze A. Jansen, Suzy Varderidou‐Minasian, Bart Westendorp, (unknown), Maarten Altelaar, Caroline A. Lindemans, Magdalena J. Lorenowicz	4
2	CFTR and colorectal cancer susceptibility: an urgent need for further studies 2024 ·Trends in cancer ·Sacha Spelier, Shelley Derksen, Regina W. Hofland, Jeffrey M. Beekman, Bahar Yetkin-Arik	2
3	New Insights in ATP Synthesis as Therapeutic Target in Cancer and Angiogenic Ocular Diseases 2024 ·Journal of Histochemistry & Cytochemistry ·Cornelis J.F. Van Noorden, Bahar Yetkin-Arik, (unknown), (unknown), (unknown), Reinier O. Schlingemann, Ingeborg Klaassen, Bernarda Majc, (unknown), (unknown), (unknown), Miloš Vittori, Mateja Erdani Kreft, Metka Novak, Barbara Breznik, Vashendriya V.V. Hira	7
4	Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy 2020 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Bahar Yetkin-Arik, Arnoud W. Kastelein, Ingeborg Klaassen, Charlotte H. J. R. Jansen, (unknown), Miloš Vittori, Aydan Bırı, (unknown), Arjan W. Griffioen, Frédéric Amant, Christianne Lok, Reinier O. Schlingemann, Cornelis J.F. Van Noorden	66
5	The role of glycolysis and mitochondrial respiration in the formation and functioning of endothelial tip cells during angiogenesis 2019 ·Scientific Reports ·Bahar Yetkin-Arik, Ilse M. C. Vogels, Patrycja Nowak‐Sliwinska, Andrea Weiss, Riekelt H. Houtkooper, Cornelis J.F. Van Noorden, Ingeborg Klaassen, Reinier O. Schlingemann	135
6	Endothelial tip cells in vitro are less glycolytic and have a more flexible response to metabolic stress than non-tip cells 2019 ·Scientific Reports ·Bahar Yetkin-Arik, Ilse M. C. Vogels, (unknown), Vincent van Duinen, Riekelt H. Houtkooper, Cornelis J.F. Van Noorden, Ingeborg Klaassen, Reinier O. Schlingemann	64
7	IGF2 and IGF1R identified as novel tip cell genes in primary microvascular endothelial cell monolayers 2018 ·Angiogenesis ·(unknown), Bahar Yetkin-Arik, (unknown), Ilse M. C. Vogels, Patrycja Nowak‐Sliwinska, Arjan W. Griffioen, Cornelis J.F. Van Noorden, Ingeborg Klaassen, Reinier O. Schlingemann	38
8	CD34 Promotes Pathological Epi-Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy (vol 11, e0157902, 2016) 2016 ·PLoS ONE ·Martin J. Siemerink, Michael R. Hughes, (unknown), (unknown), Jessica Cait, Ilse M. C. Vogels, Bahar Yetkin-Arik, Cornelis J.F. Van Noorden, Ingeborg Klaassen, Kelly M. McNagny, Reinier O. Schlingemann	1
9	CD34 Promotes Pathological Epi-Retinal Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy 2016 ·PLoS ONE ·Martin J. Siemerink, Michael R. Hughes, (unknown), (unknown), Jessica Cait, Ilse M. C. Vogels, Bahar Yetkin-Arik, Cornelis J.F. Van Noorden, Ingeborg Klaassen, Kelly M. McNagny, Reinier O. Schlingemann	27
10	Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein 2015 ·Acta Neuropathologica ·Anna C. Navis, Sanne A. M. van Lith, Sander M. J. van Duijnhoven, (unknown), Bahar Yetkin-Arik, Pieter Wesseling, Wiljan Hendriks, Hanka Venselaar, Marco Timmer, (unknown), Paul M.P. van Bergen en Henegouwen, Myron G. Best, Thomas Würdinger, Bastiaan B.J. Tops, William P. J. Leenders	32
11	Overcoming the blood–brain tumor barrier for effective glioblastoma treatment breakdown → 2015 ·Drug Resistance Updates ·Olaf van Tellingen, Bahar Yetkin-Arik, Mark C. de Gooijer, Pieter Wesseling, Tom Würdinger, Helga E. de Vries	764

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact